Built on Rigorous Science
ProJenX is a clinical-stage biotechnology company developing novel, targeted brain penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS.
At the heart of ProJenX’s approach is an innovative, patient-specific, cell-based drug discovery platform. Through a long-term research collaboration between Project ALS and researchers at Columbia University, our team drove breakthroughs in stem cell biology and created the first ALS patient-derived disease models. These models drove insights into what goes wrong with motor neurons, the brain cells affected by ALS – and how to rescue them.
At ProJenX, we are guided by ALS biology. Our lead candidate, prosetin, was identified in patient-derived models, developed for motor neuron protection, and optimized for brain penetrance.
Read more about the scientific breakthroughs behind ProJenX.
Prosetin: Changing the Trajectory of ALS
Prosetin is the first brain-penetrant MAP4K inhibitor therapy to enter clinical trials. ProJenX scientific co-founders at Columbia University have shown that prosetin is highly effective across multiple laboratory models of ALS.
What sets prosetin apart?
ALS in a Dish
Novel, brain-penetrant kinase inhibitors
Developing prosetin for people with ALS is our top priority. At the same time, we are exploring the role of MAP4K inhibition in treating other neurodegenerative disorders that trigger endoplasmic reticulum (ER) stress-mediated degeneration of neurons, and in other debilitating brain diseases in which this pathway play an established biological role.